防禦型股票成衰退重鎮:阿波羅、可口可樂與沃爾瑪為何具韌性 | AI 驅動的財商語言學習中心

防禦型股票成衰退重鎮:阿波羅、可口可樂與沃爾瑪為何具韌性

2026-05-21 00:39 0 次瀏覽 重要度 7/10
Trader Mike

Trader Mike 的深度觀點

市場策略師

實戰派交易員,專注於美股大盤、價格行為與資金流向。不談空泛理論,只看圖表與籌碼。

Prosper Junior Bakiny, The Motley Fool
Thu, May 21, 2026 at 1:50 AM CDT

Although broader equities have performed pretty well this year, recession fears are lingering. After all, we are still dealing with macroeconomic problems and rising inflation. For those especially worried that the economy will eventually succumb to these headwinds and enter a recession, it helps to buy shares of companies that can perform well even in the most challenging environments. Here are three of them: Abbott Laboratories (NYSE: ABT), Coca-Cola (NYSE: KO), and Walmart (NASDAQ: WMT). Read on to find out why these three stocks are excellent buys if there is a recession on the way.

Image source: Getty Images.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

There are several reasons Abbott Laboratories is an excellent stock to buy ahead of a recession. First, it has a large portfolio of healthcare products across four categories: Pharmaceuticals, medical devices, nutrition, and diagnostics. Many of the products it offers remain in high demand regardless of economic conditions. For instance, in nutrition, it is a market leader in baby formula, something parents aren't going to want to stop buying, no matter what happens. Within its core medical device business, Abbott Laboratories markets a range of products that help treat serious, sometimes life-threatening conditions.

Those, too, should experience resilient demand even during recessions. Second, Abbott Laboratories has several growth drivers that could help it deliver solid financial results for a long time. The company's FreeStyle Libre franchise -- a family of continuous glucose monitoring devices for diabetes patients -- has been its main growth driver for a while and still boasts plenty of white space.

Abbott Laboratories also now has a stronger presence in the cancer screening market, another promising niche, thanks to a recent acquisition. Third, Abbott Laboratories is a fantastic dividend stock. With 54 straight years of payout increases, the healthcare giant is a Dividend King, or a corporation with at least 50 consecutive years of dividend raises. Regular payouts can help buffer market losses if a recession drags broader equities down. Abbott Laboratories hasn't performed well this year, partly due to slowing top-line growth, especially within its diagnostic and nutrition businesses.

However, recent developments (including an acquisition that boosted its diagnostics segment) can help it address these problems. The stock should remain a reliable dividend payer through the next recession and beyond.

View Comments

Key Takeaways

  • 市場關注企業在衰退期間仍保持穩健需求與現金流的特性。
  • 本文聚焦阿波羅實驗室的產品多元、成長動能與長期股息分派紀錄,顯示其具備韌性。
  • 雖然目前股價表現欠佳,但近期收購提升診斷部門前景,預計將在未來衰退中維持穩定股息。
Trader Mike
8
Authenticity
真實性評分
AI 核查筆記

引用公司財報與公開收購資訊,可信度高

不想錯過任何財經快訊?

訂閱 Telegram 頻道,AI 自動為您推播每一篇深度報導與重點摘要。

立即免費訂閱

📈 相關行情圖表 由 TradingView 提供

📰 相關新聞

💬 評論 (0)

登入 後即可發表評論

💭

還沒有評論,來當第一個吧!

連結已複製